<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>58 consecutively referred, previously untreated patients with nodular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (stages III and IV) were treated with two different combination chemotherapy regimens-(<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (COP), and BCNU , <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, melphalan and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (M-2) - to compare remission induction and duration as well as survival </plain></SENT>
<SENT sid="1" pm="."><plain>The two groups were comparable for age, stage IV and histology </plain></SENT>
<SENT sid="2" pm="."><plain>The complete response for each combination was greater than 80% </plain></SENT>
<SENT sid="3" pm="."><plain>Median duration of remission for the COP-treated patients is 18 months </plain></SENT>
<SENT sid="4" pm="."><plain>Remission duration and survival are superior for M-2-treated patients </plain></SENT>
<SENT sid="5" pm="."><plain>The difference in remission duration and survival advantage is statistically significant for the M-2 protocol compared with COP at 5 years (p less than 0.01) </plain></SENT>
</text></document>